In a filing, Travere Therapeutics Inc revealed its CHIEF FINANCIAL OFFICER Cline Christopher R. unloaded Company’s shares for reported $37553.0 on May 05 ’25. In the deal valued at $21.05 per share,1,784 shares were sold. As a result of this transaction, Cline Christopher R. now holds 93,126 shares worth roughly $1.58 million.
Then, Dube Eric M sold 18,924 shares, generating $398,350 in total proceeds. Upon selling the shares at $21.05, the CHIEF EXECUTIVE OFFICER now owns 419,173 shares.
Before that, Heerma Peter sold 1,771 shares. Travere Therapeutics Inc shares valued at $37,280 were divested by the CHIEF COMMERCIAL OFFICER at a price of $21.05 per share. As a result of the transaction, Heerma Peter now holds 128,215 shares, worth roughly $2.18 million.
Cantor Fitzgerald initiated its Travere Therapeutics Inc [TVTX] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in late October from “an Equal weight” to “an Overweight”. Scotiabank began covering TVTX with “Sector outperform” recommendation on October 16, 2024. Guggenheim revised its rating on September 09, 2024. It rated TVTX as “a Buy” which previously was an “a Neutral”.
Price Performance Review of TVTX
On Monday, Travere Therapeutics Inc [NASDAQ:TVTX] saw its stock jump 1.25% to $17.01. Over the last five days, the stock has lost -21.03%. Travere Therapeutics Inc shares have fallen nearly -2.35% since the year began. Nevertheless, the stocks have risen 150.15% over the past one year.
How much short interest is there in Travere Therapeutics Inc?
A steep rise in short interest was recorded in Travere Therapeutics Inc stocks on 2025-04-30, dropping by -0.92 million shares to a total of 10.64 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 11.56 million shares. There was a decline of -8.64%, which implies that there is a negative sentiment for the stock.
